Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome)
- PMID: 27855521
- DOI: 10.1080/17512433.2017.1260000
Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome)
Abstract
Morquio A syndrome is a rare, autosomal recessive, lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS). In 2014, the use of recombinant human GALNS, elosulfase alfa, was approved in the European Union, Canada, the United States, Australia, and Brazil for the treatment of Morquio A syndrome. Elosulfase alfa is administered intravenously once-weekly at a dose of 2.0 mg/kg. Areas covered: This is a review of the efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, and other outcomes of elosulfase alfa treatment of patients with Morquio A. A discussion of other treatment considerations, limitations, and future directions in the use of elosulfase alfa is provided. Expert commentary: Pharmacokinetic studies outside of clinical trials and in 'real-world' clinical settings need to be performed. We cannot currently predict which patient is going to respond well to enzyme replacement therapy; thus, all patients should be given the option to receive treatment for at least 12 months. Additionally, accurate biomarkers for evaluating disease state and drug responsiveness would greatly aid in the treatment of patients with Morquio A. In addition, improved and innovative daily lifestyle measures are greatly needed to adequately measure clinical response and true impact on quality of life.
Keywords: Elosulfase alfa; GALNS; MPS IVA; Morquio A; enzyme replacement therapy; lysosomal storage disorder; mucopolysaccharidosis.
Similar articles
-
Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).BioDrugs. 2014 Oct;28(5):465-75. doi: 10.1007/s40259-014-0108-z. BioDrugs. 2014. PMID: 25200032 Review.
-
Elosulfase alfa.Drugs Today (Barc). 2014 Jul;50(7):475-83. doi: 10.1358/dot.2014.50.7.2177904. Drugs Today (Barc). 2014. PMID: 25101330 Review.
-
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi: 10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6. Clin Ther. 2015. PMID: 25487082 Clinical Trial.
-
Elosulfase alfa: first global approval.Drugs. 2014 Apr;74(6):713-8. doi: 10.1007/s40265-014-0210-z. Drugs. 2014. PMID: 24700469
-
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.Clin Ther. 2017 Jan;39(1):118-129.e3. doi: 10.1016/j.clinthera.2016.11.017. Epub 2016 Dec 10. Clin Ther. 2017. PMID: 27955919 Clinical Trial.
Cited by
-
A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management.Intractable Rare Dis Res. 2020 Feb;9(1):1-9. doi: 10.5582/irdr.2020.01011. Intractable Rare Dis Res. 2020. PMID: 32201668 Free PMC article. Review.
-
The factors affecting lipid profile in adult patients with Mucopolysaccharidosis.Mol Genet Metab Rep. 2017 May 18;12:35-40. doi: 10.1016/j.ymgmr.2017.05.006. eCollection 2017 Sep. Mol Genet Metab Rep. 2017. PMID: 28560179 Free PMC article.
-
Clinical and genetic characteristics of concomitant Mucopolysaccharidosis type IVA and neurogenic bladder in children: two case reports and literature review.BMC Pediatr. 2021 Jan 6;21(1):18. doi: 10.1186/s12887-020-02484-0. BMC Pediatr. 2021. PMID: 33407246 Free PMC article. Review.
-
Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.Mol Genet Metab Rep. 2021 May 25;28:100769. doi: 10.1016/j.ymgmr.2021.100769. eCollection 2021 Sep. Mol Genet Metab Rep. 2021. PMID: 34113545 Free PMC article.
-
The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.Orphanet J Rare Dis. 2022 Mar 24;17(1):136. doi: 10.1186/s13023-022-02285-x. Orphanet J Rare Dis. 2022. PMID: 35331284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
